REBECCA GROB: Open Payments
NPI 1770040248 · SLIDELL, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$861 in 41 payments from 12 companies in 2025. Trend: 2023 $1,060 · 2024 $1,248 · 2025 $861
Food & beverage: $861
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $156 |
| MERZ NORTH AMERICA, INC. | 1 | $152 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 11 | $148 |
| PFIZER INC. | 7 | $139 |
| Merck Sharp & Dohme LLC | 4 | $77 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Novartis Pharmaceuticals Corporation | 2 | $33 |
| REVANCE THERAPEUTICS, INC. | 1 | $29 |
| ABIOMED | 1 | $27 |
| Edwards Lifesciences Corporation | 1 | $27 |
Products named: Xeomin, LifeVest, CAMZYOS, ELIQUIS, VERQUVO, FARXIGA, LEQVIO, DAXXIFY.
Industry payments across LA — which companies pay providers there.
